Skip to main navigation

Skip to content

Careers
Contact Us
中文

Home
About
Research & Development
- Pipeline
- Technology Platforms
Therapies
Newsroom
Investors

Careers
Contact Us
中文

Press Releases

Overview
Press Releases
Events and Presentations
- Annual General Meeting
Corporate Governance
Stock Information
Financials
- SEC Filings
- Earnings Releases
Resources
- Email Alerts
- Contact IR

Year

Feb 21, 2023

Legend Biotech Regains Compliance with NASDAQ Listing Rule 5250(c)(2)

Jan 27, 2023

Legend Biotech Announces Phase 3 CARTITUDE-4 Study of CARVYKTI® (ciltacabtagene autoleucel) Has Met Its Primary Endpoint in the Treatment of Patients with Relapsed and Refractory Multiple Myeloma

Jan 09, 2023

Legend Biotech Announces Notification of Delinquency from The Nasdaq Stock Market LLC

Jan 03, 2023

Legend Biotech to Participate in the 41st Annual JP Morgan Healthcare Conference

Jan 02, 2023

Legend Biotech Announces Acceptance of Its New Drug Application for Ciltacabtagene Autoleucel (Cilta-Cel) in China

Pagination

First page
Previous page
Page 1
Current page 2

Displaying 11 - 15 of 15

GLOBAL HEADQUARTERS

2101 COTTONTAIL LANE

SOMERSET, NJ 08873, USA

+1-732-317-5050

Footer Links

ABOUT US
RESEARCH & DEVELOPMENT
THERAPIES
NEWSROOM
CAREERS
ETHICS & COMPLIANCE
COMPLIANCE HOTLINE
INVESTORS
COOKIE POLICY
PRIVACY POLICY
LEGAL NOTICE
CONTACT US
SITE MAP

© Legend Biotech 2023. All rights reserved. dedication

You are about to leave LegendBiotech.com